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Abstract We report the structural characterization of
plasmatic and urinary GAGs in a patient affected by MPS
II (Hunter syndrome) before and during the first 10 months
of enzyme-replacement therapy (ERT). Plasmatic GAGs
before ERT were rich in pathological DS consisting of
iduronic acid (IdoA) and composed of ~90% DDi4s and
trace amounts of disulfated disaccharides. DS was also
characterized as the main (~90%) urinary GAG mainly
composed of ~90% DDi4s with minor percentages of
monosulfated and disulfated disaccharides, in particular
DDi2,4dis. After 300 days of ERT, plasmatic DS strongly
decreased but ~14% of IdoA-rich DDi4s was still detected.
Similarly, urinary galactosaminoglycans were mainly
composed of 78% DDi4s, ~11% DDi6s and ~4% DDi0s
with the persistence of DDi2,4dis (~4%). About 40% of
IdoA-formed DDi4s were also calculated, thus confirming
that pathological DS is still present in excreted urinary
GAGs during ERT. By considering the % of IdoA, we
observed rather similar kinetics of excretion in fluids
from the beginning of the treatment. Immediately after the
first enzyme infusion, a large amount of abnormal DS is
removed from tissues reaching the blood compartment
and eliminated via the urine, and this process lasts for
about 2 weeks. After this, the percentage of IdoA-rich
material present in biological fluids remains fairly constant
over the following 9 months of treatment. To date, these
are the first data regarding plasmatic and urinary kinetics
directly measured on products released by the activity of
the recombinant enzyme Idursulfase, iduronate-2-sulfatase,
evaluated using specific and sensitive analytical procedures.
Abbreviations
DDi0s DUA-(1!3)-GalNAc
DDi2,4dis,DDi-dis B DUA-2s-(1!3)-GalNAc-4s
DDi2,6dis,DDi-dis D DUA-2s-(1!3)-GalNAc-6s
DDi4,6dis,DDi-dis E DUA-(1!3)-GalNAc-4,6dis
DDi4s DUA-(1!3)-GalNAc-4s
DDi6s DUA-(1!3)-GalNAc-6s
CETAB Cetyltrimethyl-ammonium bromide
CS Chondroitin sulfate
DMB 1,9-Dimethylmethylene blue
DS Dermatan sulfate
ERT Enzyme-replacement therapy
GAG Glycosaminoglycan
GlcA Glucuronic acid
HS Heparan sulfate
IdoA Iduronic acid
MPS Mucopolysaccharidoses
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Introduction
Mucopolysaccharidoses (MPS) are a group of rare genetic
disorders of glycosaminoglycan (GAG) catabolism caused
by a deficiency in the activity of a single specific lysosomal
enzyme required for GAG degradation (Neufeld and
Muenzer 2007; Meikle et al. 1999; Fuller et al. 2004a;
Martins et al. 2009). These diseases are biochemically
characterized by an accumulation of intact and partially
degraded polysaccharides within lysosomes and in
biological fluids (Burlingame et al. 1981; Fuller et al.
2004a; Fuller et al. 2004b; Martins et al. 2009; Coppa et al.
2010). The GAG accumulation results in progressive
cellular damage, which can affect multiple organ systems
and lead to organ failure, cognitive impairment, and
reduced life expectancy.
Contrary to other MPS, MPS II, also known as Hunter
syndrome, is an X-linked recessive disorder generally
affecting only males, although rare female patients with
MPS II have been described due to an X-autosome
translocation and nonrandom X-chromosome inactivation
in a carrier female (Tuschl et al. 2005). MPS II is caused by
a deficiency of the lysosomal enzyme iduronate-2-sulfatase
that selectively catalyzes the hydrolysis of O-sulfate esters
from iduronate-2-sulfate belonging to heparan sulfate (HS)
and dermatan sulfate (DS) macromolecules (Coppa et al.
1973; Sj€oberg et al. 1973). MPS II affects multiple organs
and physiological systems and has a variable onset age and
variable rate of progression (Martin et al. 2008). MPS II is
presently classified into two clinically distinct forms, mild
and severe. Deficient enzyme activity leads to common
features including facial dysmorphism, organomegaly,
joint stiffness and contractures, pulmonary dysfunction,
myocardial enlargement and valvular dysfunction, and
neurological involvement (Martin et al. 2008). In patients
with neurological involvement, intelligence is impaired,
and death usually occurs in the second decade of life,
whereas those patients with minimal or no neurological
involvement may survive into adulthood with normal
intellectual development (Martin et al. 2008).
Enzyme-replacement therapy (ERT), along with hemato-
poietic stem cell transplantation (HSCT), has emerged as
a new treatment for MPS disorders, including Hunter
syndrome, and they are the standard of care worldwide for a
number of MPS diseases (Wraith 2009). The rationale for
ERT is to provide the patient with active enzyme supplied
exogenously through regular infusions. Idursulfase
(Elaprase®, Shire Human Genetic Therapies, Inc.,
Cambridge, MA), a recombinant form of human iduronate-
2-sulfatase, has been commercially available since 2006
(Okuyama et al. 2010; Muenzer et al. 2007; Muenzer et al.
2006). Benefits in patients with no baseline cognitive
impairment were found in their walking and respiratory
capacities, decreased liver and spleen volume, and in the
reduction of urinary GAG levels (Okuyama et al. 2010;
Muenzer et al. 2007; Muenzer et al. 2006). However,
apart from a general aspecific reduced urinary excretion
of GAGs observed during these clinical trials with
idursulfase performed using a generic dye-binding assay
with 1,9-dimethylmethylene blue (DMB) (Coppa et al.
1987; de Lima et al. 2007), no detailed analyses of plasma
and urinary GAG composition and structure in MPS II
patients during ERT have been published or are available.
In a previous study (Coppa et al. 2010), urinary and
plasmatic GAGs were analyzed in two patients with the
Hurler–Scheie form of MPS I subjected to ERT for 6 years,
before and during treatment regimens. ERT at the standard
dose was found to be unable to definitively eliminate DS
from the urine, and a variable effect on GAGs was also
observed depending on each administration. In this new
research, we performed an accurate quantitative and
structural characterization of high molecular mass GAGs
present in the urine and plasma of a 3-year-old subject
affected by the severe form of MPS II, before and during
the first 10 months of ERT with Idursulfase, with the
prospect of gaining a better understanding of the effect
of therapy on the metabolic fate of these complex macro-
molecules.
Methods
Materials
Microcon YM-3 filters of 0.45 mm with an MM cutoff of
3,000 Da were from Millipore (Billerica, MA, USA).
Chondroitinase ABC [E.C. 4.2.2.4], chondroitinase B [no
EC number], and proteinase K [3.4.21.64] were purchased
from Sigma-Aldrich (St. Louis, MO, USA). DMB (research
grade) was purchased from Serva (Heidelberg, Germany).
Unsaturated hyaluronic acid and chondro/dermato disac-
charides were from Seikagaku Corporation (Tokyo City,
Japan). HS from beef spleen, CS from bovine trachea, and
DS from beef mucosa were purified as previously reported
(Volpi and Maccari 2002; Volpi and Maccari 2009). Highly
pure (>98%) first European pharmacopoeia CS Standard
manufactured by Bioiberica (www.bioiberica.com/) and
approved in 2004 as Chemical Reference Substance
(CRS) by the European Pharmacopeia Commission was
used for quantitative evaluation. All the other reagents were
analytical grade generally supplied by Sigma-Aldrich.
MPS II Patient
MM is a male born at 41 weeks of gestation, after a normal
pregnancy and delivery. At birth, weight was 4.035 kg
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(90th percentile), length 51 cm (50th percentile) and head
circumference 35 cm (50th percentile). He is the second
child with healthy nonconsanguineous parents, with no
family history of genetic diseases or mental retardation. The
neonatal period and early psychomotor development
were normal. In particular, he acquired the sitting
position at 7 months and he began to walk at 14 months.
At 8 months of age he suffered from catarrhal otitis.
Afterwards, he underwent a surgical inguinal hernia. The
patient was first referred to the Pediatric Division of
the Polytechnic University of the Marche, at the age
of 2 years and 9 months as his pediatric neurologist, who
was following him for his speech delay, sleep disorders
and hyperactivity, noticed macrocrania and a slightly
coarse face. On physical examination his weight was
19.1 kg (>97th percentile), length 96 cm (50th percentile)
and head circumference 55 cm (>97th percentile). He
showed coarse facial features including frontal bossing,
depressed nasal bridge and anteverted nostril. Macroglos-
sia, hypertrophic tonsils and mucopurulent coryza were
also present. The abdomen was protuberant, with an evident
umbilical hernia. The lower liver margin was 3 cm
below the ribs while the spleen was unremarkable. Thick
skin, hirsutism and wiry hair were also noticed. He had
mild dorsolumbar gibbus, claw hands, mild elbow flexion
contractures and unstable gait. Ecocardiographic evaluation
revealed a moderate mitral valve insufficiency. Following
neuropsychological evaluation, an I.Q. of 45 was found.
He was hyperactive, aggressive, with poor socialization
and absence of expressive language. Audiometry demon-
strated hearing loss requiring hearing aids. The bone X-ray
survey showed the typical findings of multiple dysostosis:
hip hypoplasia, ovoid shape of lumbar vertebral bodies,
V-shaped distal ulnar and radial extremities, short and
broad metacarpal bones and enlargement of the
sella turcica. Urinary GAGs excretion was 1018 mg/mg
creatinine (normal value for age: 14–90 mg/mg), and
electrophoretic urinary GAGs characterization on acetate
of cellulose showed the presence of bands corresponding to
DS and HS. Plasma iduronate sulfatase activity was
0.8 nM/ml/4 h (normal value: 12.9–28.0). Molecular
analysis revealed the P120R mutation on Xq28. On the
basis of the above results and of the clinical evaluation, the
diagnosis of mucopolysaccharidosis type II (Hunter syn-
drome), severe form, was made. After 10 months of ERT,
on physical examination his weight was 23.0 kg (>97th
percentile), length 107 cm (90th percentile) and head
circumference 56 cm (>97th percentile). Cardiovascular
abnormalities and hearing loss had stabilized, hepatomegaly
had been resolved and joint stiffness had improved. On the
contrary, the neuropsychological evaluation did not show
any significant improvement.
Patient Sample Collection
Daily morning urine samples were collected from our
subject before and during the first 10 months of ERT and
frozen at 20C for analytical investigation.
Blood was collected from the patient before any ERT
and treated as reported below. Blood samples were
withdrawn immediately before, and at 1 and 3 h after
enzyme infusion, and at different times and days after
treatment, over ten consecutive months of ERT, collected in
tubes containing citrate as an anticoagulant, and the plasma
obtained was stored at 20C for analytical investigation.
Structural Characterization of Plasma and Urine GAGs
The adopted methodology for the determination of the
structure and properties of biological fluid GAGs has been
reported in detail in (Coppa et al. 2010).
After extraction and purification from 500 ml of plasma
(see Coppa et al. 2010), the crude retained GAG fraction
was dissolved in 50 ml distilled water. Two aliquots of
10 mL were freeze-dried, dissolved in 30 mL Tris-Cl
100 mM pH 8.0 and treated with 20 mL chondroitinase
ABC or 20 mL chondroitinase B. Unsaturated CS/DS
disaccharides were separated and quantified by HPLC and
postcolumn derivatization with 2-cyanoacetamide and
fluorimetric detection (Volpi 2004). The percentage deter-
mination of each disaccharide was obtained by means of
specific calibration curves performed with authentic stand-
ards manufactured by Seikagaku Corporation.
For the quantitation of total urinary GAGs, 100 mL of
urine was subjected to DMB assay performed according to
(Coppa et al. 1987, 2010). The final quantitative data were
normalized for mg creatinine and expressed as mg GAGs/
mg creatinine. Furthermore, 5 mL of urine samples from
the Patient before any ERT and during treatment was
treated with 5% CETAB as previously reported in detail
(Dietrich et al. 1993; Maccari et al. 2003; Coppa et al.
2010) and, after extraction, GAGs were dissolved in 200 ml
distilled water for further analyses. 40 ml of human urine
extracts, not treated or degraded with chondroitinase ABC
or B, was separated and quantified by agarose-gel electro-
phoresis (20 ml layered on gel) and densitometric scanning
by means of specific calibration curves as reported
elsewhere (Volpi 1993; Volpi and Maccari 2002, 2009)
performed by layering on each gel increasing amounts,
from 0.5 to 4 mg of the first European pharmacopoeia CS
Standard manufactured by Bioiberica (www.bioiberica.
com/) (Volpi 2007). The final quantitative data were
normalized for mg creatinine and expressed as mg GAGs/
mg creatinine. Another 20 ml containing unsaturated
disaccharides was separated and quantified by HPLC and
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UV detection at 232 nm. The percentage determination of
each disaccharide was obtained by means of specific
calibration curves performed with authentic standards
manufactured by Seikagaku Corporation.
Results
Plasma GAG Composition
It is known that normal human plasma contains low
amounts of a major undersulfated CS (Juvani et al. 1975;
Volpi and Maccari 2005) covalently bound to an inter-
trypsin inhibitor (bikunin) with a chain molecular mass of
approx. 6–8 kDa (Chi et al. 2008) mainly constituted by
approx. 40–60% nonsulfated disaccharide and 40–60% 4-
sulfated disaccharide with trace amounts of 6-sulfated
disaccharide (Juvani et al. 1975; Volpi and Maccari 2005;
Coppa et al. 2010) (see as an example Fig. 1a,
+ chondroitinase ABC), and totally composed of glucuronic
acid (GlcA) with no trace of iduronic acid (IdoA) typical of
DS (see as an example Fig. 1b, + chondroitinase B). As a
consequence, for an accurate evaluation of plasmatic CS/
DS species, GAGs were subjected to treatment with
chondroitinases ABC and B for the determination of
disaccharide species and presence of IdoA.
Plasmatic GAG before any ERT treated with chondroi-
tinase ABC (Fig. 2a, + chondroitinase ABC) was found to
be composed of ~70% DDi4s, ~24% DDi0s ~5% DDi6s
and trace amounts of disulfated disaccharides (Table 1).
The charge density was calculated to be 0.77 with a 4s/0s
ratio of 2.88. Furthermore, after degradation with chon-
droitinase B (Fig. 2b, + chondroitinase B), a single
disaccharide species was detected, ~90% DDi4s, with
~6% DDi6s, and trace amounts of disulfated disaccharides.
As a consequence, the plasmatic polysaccharide in our
MPS II patient before any ERT was constituted by ~34%
Fig. 1 HPLC separation and postcolumn derivatization with fluores-
cence detection of unsaturated nonsulfated and variously sulfated
disaccharides of the galactosaminoglycans extracted from plasma
of a 3-year-old healthy pediatric subject subjected to chondroitin
ABC lyase (A, +lyase ABC) or chondroitin B lyase (B, +lyase B)
digestions. DDi0s, DUA-(1!3)-GalNAc. DDi4s, DUA-(1!3)-
GalNAc-4s. DDi6s, DUA-(1!3)-GalNAc-6s
Fig. 2 HPLC separation and postcolumn derivatization with fluores-
cence detection of unsaturated nonsulfated and variously sulfated
disaccharides of the galactosaminoglycans extracted from plasma of
the MPS II patient before any enzyme-replacement therapy (day 5)
subjected to chondroitin ABC lyase (A, +lyase ABC) or chondroitin B
lyase (B, +lyase B) digestions. DDi0s, DUA-(1!3)-GalNAc. DDi4s,
DUA-(1!3)-GalNAc-4s. DDi6s, DUA-(1!3)-GalNAc-6s.
DDi2,4dis, DDi-dis B, DUA-2s-(1!3)-GalNAc-4s. DDi2,6dis,
DDi-dis D, DUA-2s-(1!3)-GalNAc-6s. DDi4,6dis, DDi-dis E,
DUA-(1!3)-GalNAc-4,6dis
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IdoA mainly associated with DDi4s disaccharide with the
remaining 66% being formed by expected undersulfated CS
composed of GlcA with typical disaccharides DDi0s and
DDi4s.
After 300 days of continuous ERT, plasmatic GAG was
found to be composed of ~63% DDi4s, ~36% DDi0s
and ~1% DDi6s (Fig. 3a, + chondroitinase ABC) with a
decrease in the charge density (0.64) and 4s/0s ratio (1.73)
compared to the polysaccharide before treatment showing a
progression towards the more physiological undersulfated
CS (Table 1). To confirm this, treatment with chondroiti-
nase B (Fig. 3b, + chondroitinase B) showed a strong
decrease in the DDi4s disaccharide associated with IdoA
being ~14% of the disaccharides produced by ABC.
The previous structural plasmatic GAG evaluation
showed, along with the physiological undersulfated CS,
the presence of an abnormal polysaccharide characterized
as DS due to the presence of a high percentage of DDi4s
disaccharide associated with IdoA, as expected for MPS II
disorder. Over the 10-month period, ERT reduced the
percentage of this abnormal polymer up to 85%, as
illustrated in Fig. 3, but was unable to totally remove
it from the blood. In fact, after 10 months of treatment,
~13–15% of this DS was still detected. Finally, as is
evident from Fig. 4, a strong increase in the plasmatic
IdoA-composed polysaccharide percentage was measured
immediately after the first enzyme infusion, after 1 h, with
a maximum after 3 h, then a continuous decrease in the
8–15 days following treatment. After this, a constant
plasmatic content of IdoA-formed GAGs percentage was
observed. We can suppose that, in our patient, immediately
after the first enzyme administration, a large amount of
abnormal DS is removed from tissues reaching the blood
compartment, and this process lasts for approximately the
following 2 weeks following the first infusion.
Urine GAG Composition
Urine GAGs collected before ERT and at different days and
times during therapy over a period of 10 months were
extracted by means of a conventional method (Dietrich
et al. 1993; Maccari et al. 2003; Buzzega et al. 2010) and
Table 1 Structural characterization of plasmatic galactosaminogly-
cans of the MPS II patient before and after 300 days of continuous
ERT
Patient MPS II
Before ERT After 10 months
of ERT
DDi0s (%) 24.2 36.2
DDi6s (%) 4.8 1.2
DDi4s (%) 69.6 62.6
DDi2,6dis (%) 0.0 0.0
DDi4,6dis (%) 1.1 0.0
DDi2,4dis (%) 0.3 0.0
Charge density 0.77 0.64
4s/0s Ratio 2.88 1.73
IdoA/GlcA Ratio (%) 34/66 14/86
The results are the mean of three different analyses. The coefficient of
variation % was always found to be lower than 15% for all analyses.
The charge density was calculated considering the presence and the
percentage of carboxyl and sulfate groups for each disaccharide. 4s/0s
ratio: ratio between 4-sulfated disaccharide, DDi4s, and the non-
sulfated disaccharide, DDi0s. The percentages of the two different
uronic acids have been calculated by means of HPLC after treatment
with chondroitinases ABC and B. DDi0s, DUA-(1!3)-GalNAc.
DDi4s, DUA-(1!3)-GalNAc-4s. DDi6s, DUA-(1!3)-GalNAc-6s.
DDi2,4dis, DDi-dis B, DUA-2s-(1!3)-GalNAc-4s. DDi2,6dis,
DDi-dis D, DUA-2s-(1!3)-GalNAc-6s. DDi4,6dis, DDi-dis E,
DUA-(1!3)-GalNAc-4,6dis
Fig. 3 HPLC separation and postcolumn derivatization with fluores-
cence detection of unsaturated nonsulfated and variously sulfated
disaccharides of the galactosaminoglycans extracted from plasma of
the MPS II patient after 300 days of continuous treatment (day 300)
subjected to chondroitin ABC lyase (A, +lyase ABC) or chondroitin B
lyase (B, +lyase B) digestions. DDi0s, DUA-(1!3)-GalNAc. DDi4s,
DUA-(1!3)-GalNAc-4s. DDi6s, DUA-(1!3)-GalNAc-6s.
DDi2,4dis, DDi-dis B, DUA-2s-(1!3)-GalNAc-4s. DDi2,6dis, DDi-
dis D, DUA-2s-(1!3)-GalNAc-6s. DDi4,6dis, DDi-dis E, DUA-
(1!3)-GalNAc-4,6dis
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analyzed by means of agarose-gel electrophoresis (Fig. 5)
and densitometric evaluation for quantitative acquisition
(then data were normalized for mg creatinine, Fig. 6a).
Furthermore, total GAGs were determined directly in urine
samples by a standard colorimetric assay accepted by the
Guidelines for the management of MPS (Martins et al.
2009) by using DMB (Fig. 6a) (normal range of DMB
values for ages ranging from 22 to 86 mg/mg creatinine). As
is evident from the electrophoresis, a high content of a band
having a migration position similar to standard DS was
observed before and during ERT along with minor amounts
of bands similar to standard CS (see 3, 0, 1 and 8 for
example) and standard HS (see 0, 13, 15 and 26 for
example). Evaluation of the total content of urinary GAGs
Fig. 4 Percentage of iduronic acid-composed plasmatic galactosami-
noglycans depending on the days of enzyme-replacement therapy
measured by HPLC separation of disaccharides obtained by treatment
with chondroitin ABC and B lyases (see Figs. 2 and 3 as examples).
Days and times of plasma collection are the same as indicated in
Fig. 5 for urine samples characterization
Fig. 5 Agarose-gel electrophoresis stained with toluidine blue of
GAGs extracted from the urine of the MPS II patient before any
enzyme-replacement therapy (-5, -4, -3) and on different days (the first
line of label) and times (the second line of label) of treatment, also
with the indication of the moment of enzyme infusion (the third line of
label) up to 301 days. Post indicates a not fully specified time after
enzyme infusion. Mix, GAGs standard. CS chondroitin sulfate, DS
dermatan sulfate, HS heparan sulfate, FM fast-moving heparin, SM
slow-moving heparin. Quantitative analysis was performed by means
of specific calibration curves constructed by layering on each gel
increasing amounts, from 0.5 to 4 mg, of the first European
pharmacopoeia CS Standard (not shown in the figure)
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performed by DMB assay and agarose-gel electrophoresis
normalized for mg creatinine is illustrated in Fig. 6a.
A strong increase in the total urinary GAGs was measured
immediately after the first infusion of enzyme by DMB
assay (after 1–3 h, ~ +70%) and agarose-gel electrophoresis
(~ +80% after 1 h and ~ +40% after 3 h) followed by lower
values for the 8 days following treatment. Fairly similar
behavior was observed after the second infusion with
a strong increase in urinary GAGs during the first few
hours immediately after administration followed by
a constant decrease (Fig. 6a). Further infusions after
16, 26, 120 and 300 days from the first treatment produced
less important modifications in the urinary GAGs levels.
Furthermore, after 10 months of therapy, the total content of
urinary GAGs performed by DMB assay still produced
higher values than normal (normal range of 22–86 mg/mg
creatinine) according to other studies showing a reduction
but not a normalization of urinary DMB values after
many months of ERT (Alcalde-Martín et al. 2010;
Muenzer et al. 2011).
We should consider that the DMB assay is able to detect
high molecular mass GAGs along with fragments (Whitley
et al. 1989; de Lima et al. 2007), contrary to agarose-gel
electrophoresis, which is capable of evaluating molecules
having a molecular mass greater than ~1500 (Volpi 1993;
Volpi and Maccari 2002). As a consequence, as illustrated
in Fig. 6b, by comparing the two data we can calculate the
amount of urinary GAG fragments lower than ~1500
eliminated during ERT having a behavior comparable to
total GAGs as well as to high molecular mass DS. In fact,
a large amount of these low molecular mass fragments
was measured immediately after the first enzyme infusion
with a continuous decrease over the following 10 days then
remaining fairly constant up to 10 months of treatment
(Fig. 6b). Finally, after the first two enzyme administrations
a constant decrease in the urinary content of high molecular
Fig. 6 (a) Total amounts of GAGs expressed as mg/mg creatinine in
the urine of the MPS II patient before any enzyme-replacement
therapy (-5, -4, -3) and on different days and times during enzyme-
replacement treatment determined by agarose-gel electrophoresis (see
Fig. 5) and DMB assay. (b) Amounts of urinary GAG fragments lower
than ~1,500 Da expressed as mg/mg creatinine and determined by
comparing DMB data with agarose-gel electrophoresis results. Days
and times of urine sample collection are the same as indicated in Fig. 5
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mass GAGs was observed but with values still higher than
normal subjects for age and, according to the results
obtained in plasma, we can suppose that immediately
after the first enzyme administrations, a high amount of
abnormal DS is removed from tissues reaching the blood
compartment and urines in particular during the 2 weeks
subsequent to the beginning of therapy.
The main urinary GAG band detected in Agarose-gel
electrophoresis before ERT was definitively characterized
as DS by specific treatment with chondroitin ABC and B
lyases, this last enzyme being able to degrade polymers
consisting of iduronic acid typical of DS species (Volpi and
Maccari 2009). Urinary galactosaminoglycans, i.e., CS
and DS, in our MPS II patient before ERT (Fig. 7a) were
found to be mainly composed of ~90% DDi4s, ~3% DDi6s
and ~3% DDi0s (Table 2). Minor but significant percen-
tages of disulfated disaccharides, in particular DDi2,4dis
(2%) typical of DS (Volpi 2009; Volpi and Maccari 2009),
were also observed (Table 2). As a consequence, a
polysaccharide very rich in 4-sulfated groups on the
hexosamine (4s/6s ratio of ~30) and having a charge
density of ~1 (Table 1) was detected in the MPS II subject.
Moreover, the use of chondroitinase B (Fig. 7b) showed the
presence essentially of DDi4s corresponding to about 89%
of the amount of the same disaccharide obtained after
chondroitinase ABC digestion in our patient (Table 2),
confirming that excreted urinary galactosaminoglycans are
essentially composed of 90% DS with ~10% CS.
After 10 months of continuous ERT, galactosaminogly-
cans in urine were mainly composed of 78% DDi4s, ~11%
DDi6s and ~4% DDi0s (Table 2) showing a polysaccharide
still having a high 4s/6s ratio (~7) but lower than it was
prior to therapy demonstrating a DS reduction of ~55–60%.
Minor but significant percentages of disulfated disacchar-
ides, in particular DDi2,4dis (~4%), were also detected
(Fig. 8a) (Table 2), resulting in an average charge density of
~1.0 for the polysaccharide chains. The use of chondroiti-
nase B (Fig. 8b) showed the presence essentially of DDi4s
corresponding to ~40% of disaccharides produced by
chondroitinase ABC, thus confirming that excreted urinary
GAGs during ERT are a mixture of CS (~60%) and DS
(~40%). Finally, Fig. 9 illustrates as an example the urinary
galactosaminoglycan disaccharide profile of a normal
subject after treatment with both lyases showing the
absence of DDi4s produced by chondroitinase B.
Fig. 7 HPLC separation and UV detection at 232 nm of unsaturated
nonsulfated and variously sulfated disaccharides of the galactosami-
noglycans extracted from the urine of the MPS II patient before any
enzyme-replacement therapy (see day 5 of Fig. 5) subjected to
chondroitin ABC lyase (a) or chondroitin B lyase (b) digestions.
DDi0s, DUA-(1!3)-GalNAc. DDi4s, DUA-(1!3)-GalNAc-4s.
DDi6s, DUA-(1!3)-GalNAc-6s. DDi2,4dis, DDi-dis B, DUA-2s-
(1!3)-GalNAc-4s. DDi2,6dis, DDi-dis D, DUA-2s-(1!3)-GalNAc-
6s. DDi4,6dis, DDi-dis E, DUA-(1!3)-GalNAc-4,6dis
Table 2 Structural characterization of the galactosaminoglycans
component of the urine of the MPS II patient before and after
300 days of continuous ERT
Patient MPS II
Before ERT After 10 months
of ERT
DDi0s (%) 3.3 3.8
DDi6s (%) 3.0 11.5
DDi4s (%) 89.7 78.1
DDi2,6dis (%) 0.4 0.0
DDi4,6dis (%) 1.5 0.4
DDi2,4dis (%) 2.1 6.2
Charge density 1.00 1.03
4s/6s Ratio 29.9 6.8
IdoA/GlcA Ratio (%) 89/11 40/60
The results are the mean of three different analyses. The coefficient of
variation % was always found to be lower than 15% for all analyses.
The charge density was calculated considering the presence and the
percentage of carboxyl and sulfate groups for each disaccharide. 4s/6s
ratio: ratio between 4-sulfated disaccharide, DDi4s, and the sulfated
disaccharide in position 6 of the N-acetyl-galactosamine unit, DDi6s.
The percentages of the two different uronic acids have been calculated
by means of SAX-HPLC after treatment with chondroitinases ABC
and B. DDi0s, DUA-(1!3)-GalNAc. DDi4s, DUA-(1!3)-GalNAc-
4s. DDi6s, DUA-(1!3)-GalNAc-6s. DDi2,4dis, DDi-dis B, DUA-2s-
(1!3)-GalNAc-4s. DDi2,6dis, DDi-dis D, DUA-2s-(1!3)-GalNAc-
6s. DDi4,6dis, DDi-dis E, DUA-(1!3)-GalNAc-4,6dis
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The urinary IdoA-composed polysaccharide percentage
is reported in Fig. 10 depending on the days and hours
before and during ERT. A trend fairly similar to that
measured in plasma (see Fig. 4) was observed in the urine,
in particular an increase in DS was measured after the first
enzyme infusion followed by a progressive decrease up to
the second administration, after which a new DS increase
was evident, followed by a continuous progressive
decrease. However, as in the case of plasma, after 300 days
of treatment, ERT was unable to totally remove DS from
the urine, being still present in a high percentage of (~40%).
Discussion
ERT with idursulfase has been commercially available since
2007 and early access programs have been established since
2005. However, limited information on the effects of ERT on
principal accumulated macromolecules, GAGs, responsible
for the pathological conditions is available to date. In recent
clinical studies (Muenzer et al. 2011; Alcalde-Martín et al.
2010; Okuyama et al. 2010), urinary GAG excretion was
found to decrease rapidly within the first 3 months of ERT
treatment, simply by DMB assay evaluation.
In a previous paper (Coppa et al. 2010), we characterized
the plasmatic and urinary GAGs of two patients with the
Hurler–Scheie form of MPS I before ERT and after a 6-year
period of treatment. This previous study showed, despite an
evident clinical efficacy, the reduced capacity of ERT by
infusion of recombinant human a-L-iduronidase at the
standard dose to definitively eliminate pathological DS
from the urine. In this new study, we applied a fairly similar
analytical methodology to characterize plasmatic and
urinary GAGs in a subject affected by the severe form of
MPS II, before and during the first 10 months of ERT, with
a recombinant form of human iduronate-2-sulfatase. The
defect of the two enzymes responsible for MPS I and II
gives rise to the accumulation of the same high molecular
mass GAGs, i.e., urinary DS and HS (the latter mainly
present in the form of low molecular mass fragments, see
below). In fact, also in the MPS II patient before ERT,
urinary galactosaminoglycans were mainly composed of
~90% DDi4s, with minor but significant percentages of
Fig. 8 HPLC separation and UV detection at 232 nm of unsaturated
nonsulfated and variously sulfated disaccharides of the galactosami-
noglycans extracted from the urine of the MPS II patient after
300 days of continuous treatment (see day 300 of Fig. 5) subjected to
chondroitin ABC lyase (a) or chondroitin B lyase (b) digestions.
DDi0s, DUA-(1!3)-GalNAc. DDi4s, DUA-(1!3)-GalNAc-4s.
DDi6s, DUA-(1!3)-GalNAc-6s. DDi2,4dis, DDi-dis B, DUA-2s-
(1!3)-GalNAc-4s. DDi2,6dis, DDi-dis D, DUA-2s-(1!3)-Gal-
NAc-6s. DDi4,6dis, DDi-dis E, DUA-(1!3)-GalNAc-4,6dis
Fig. 9 HPLC separation and UV detection at 232 nm of unsaturated
nonsulfated and variously sulfated disaccharides of the galactosami-
noglycans extracted from the urine of a normal pediatric subject
treated with chondroitin ABC lyase (a) or chondroitin B lyase (b)
digestions. DDi0s, DUA-(1!3)-GalNAc. DDi4s, DUA-(1!3)-Gal-
NAc-4s. DDi6s, DUA-(1!3)-GalNAc-6s
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disulfated disaccharides and ~90% IdoA. This should
explain the presence of many similar clinical features for
MPS I and II. Furthermore, in a recent study (Coppa et al.
2011), we found a correlation between the amount of total
urinary GAGs and the severity of MPS type I and II. As a
consequence, we can suppose that in our MPS II patient
affected by a severe form, ERT would be less effective to
totally remove the high content of pathological DS.
Along with high molecular mass GAGs (Burlingame et al.
1981; Coppa et al. 2010), also fragments and HS/DS
oligosaccharides are excreted in MPS I urine (Fuller et al.
2004b; Coppa et al. 2011). In fact, by using a specific
analytical approach, we were able to detect in the urine a high
content of glucosamine demonstrating that HS is mainly
excreted as fragments and oligomers not determined by
agarose-gel electrophoresis due to its incapacity to detect
molecules having a molecular mass lower than approx.1500
(Volpi and Maccari 2002). Furthermore, the presence of a low
content of HS having a molecular mass greater than ~1,500 is
also evident in agarose-gel electrophoresis in some urine
samples (see Fig. 5, the faint band having lower mobility).
As DS accumulated in MPS II is obviously composed of
IdoA as opposed to physiological undersulfated CS present
in plasma and CS in urine, we used the percentage of IdoA
calculated in the total galactosaminoglycans to monitor the
efficacy of ERT immediately after the first enzyme infusion
and over the 10-month treatment period. Fairly similar
kinetics of IdoA-rich material excretion was observed in
plasma and urine from the beginning of treatment. A strong
increase in the plasmatic IdoA-composed polysaccharide
percentage was measured immediately after the first
enzyme infusion, followed by a continuous decrease in
the 8–15 days following the beginning of treatment. After
this, an almost constant plasmatic content of the IdoA-
formed GAGs percentage was observed. In the urine, an
increase in DS excretion was measured after the first and
second enzyme infusion followed by a continuous progres-
sive decrease. We can suppose that immediately after the
first enzyme administrations, a large amount of abnormal
DS is removed from tissues reaching the blood compart-
ment and eliminated via the urine, and thereafter only
minimal changes have been observed. This process lasts for
approximately 2 weeks after the first infusion. After this,
the percentage of IdoA-rich material present in plasma and
eliminated with the urine remains fairly constant over the
following months of treatment. To date, these are the first
data regarding plasmatic and urinary kinetics directly
measured on products released by the activity of the
recombinant enzyme Idursulfase, iduronate-2-sulfatase.
Plasma GAGs in MPS I subjects after 6 years of ERT
were found to be comparable to those of normal subjects
(Coppa et al. 2010), while a pathological high molecular
mass DS was still found in the urine having a high
percentage of 4-sulfated disaccharide and iduronic acid
(~60%) mainly associated with DS. Interestingly, a rather
similar trend was observed in the plasmatic and urinary
GAGs in our MPS II subject after several months of ERT
evaluated in this study. In fact, after 10 months’ treatment, a
high percentage (~40%) of DS was detected in the urine,
and plasma still showed ~14% of IdoA-associated material.
ERT performed by infusion of recombinant human a-L-
iduronidase to treat MPS I or iduronate-2-sulfatase for MPS
II at the standard doses does not totally remove DS from
urine (and also plasma in our MPS II Patient) after
prolonged treatment even if they are very effective in
eliminating large amounts of this pathological GAG just
after the first weeks following the beginning of enzyme
infusion. In fact, after 10 months’ treatment, a very low
Fig. 10 Percentage of iduronic acid-composed urinary galactosami-
noglycans depending on days of enzyme-replacement therapy
measured by HPLC separation of disaccharides obtained by treatment
with chondroitin ABC and B lyases (see Figs. 7 and 8 as examples).
Days and times of urine sample collection are the same as indicated in
Fig. 5
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content of high molecular mass polymer(s) was observed
compared to pretreatment on the contrary of fragments still
present in the urine in relatively high amounts.
According to the previous study on MPS I patients
subjected to ERT, the presence of high molecular mass DS
in the urine of the MPS II subject treated with iduronate-2-
sulfatase was found to be inconstant over one continuous
week of observation (see for example Fig. 6 for days 8, 9, 10,
11, 12, 13, 14 and 15 after infusion), thus confirming the
incomplete effectiveness of ERT at the present standard dose
to maintain a constant level of physiological GAGs, as we
qualitatively characterized still abnormal levels of the patho-
logical polymer along with normally excreted CS in the urine.
Contrary to this new research in which we measured
~14% of IdoA-associated material, in the previous study we
were unable to detect any pathological DS in human plasma
during ERT. This difference may be due to several reasons,
such as different periods of treatment (10 months versus
6 years), or possible variable effects depending on the
subjects. However, the incapacity of ERT, after 10 months’
treatment, to totally remove pathological products derived
from the condition of MPS II disorder in our patient (severe
form) focuses attention on the possibility that the present
therapeutic regimen might not be sufficient to totally
remove the accumulation of lysosomal GAGs. Therefore,
the present specific and sensitive measurements and
structural characterization of human biological fluid GAGs,
even if applied in a unique MPS II patient, would be
extremely helpful for an accurate evaluation of the kinetics
of catabolic products following possibly more effective
and new therapeutic interventions, such as ERT for recent
clinical trials (for MPS type VI) (Wraith 2009) or
hematopoietic stem cell transplantation (HSCT).
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The Concise Sentence Take-Home Message
Before ERT and over 10 months of enzyme infusion,
glycosaminoglycans in urine and plasma were analyzed in a
patient with severe MPS II (Hunter syndrome) and new
data and a better understanding of the metabolic fate of
these macromolecules have been obtained.
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